151 related articles for article (PubMed ID: 15087726)
1. Assessment of sequential enhancement patterns of focal nodular hyperplasia and hepatocellular carcinoma on mangafodipir trisodium enhanced MR imaging.
Savellano DH; Köstler H; Baus S; Mössinger M; Gratz KF; Weimann A; Galanski M
Invest Radiol; 2004 May; 39(5):305-12. PubMed ID: 15087726
[TBL] [Abstract][Full Text] [Related]
2. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.
Scharitzer M; Schima W; Schober E; Reimer P; Helmberger TK; Holzknecht N; Stadler A; Ba-Ssalamah A; Weber M; Wrba F
J Comput Assist Tomogr; 2005; 29(2):181-90. PubMed ID: 15772534
[TBL] [Abstract][Full Text] [Related]
3. Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging.
Coffin CM; Diche T; Mahfouz A; Alexandre M; Caseiro-Alves F; Rahmouni A; Vasile N; Mathieu D
Eur Radiol; 1999; 9(3):444-9. PubMed ID: 10087113
[TBL] [Abstract][Full Text] [Related]
4. Characterization of focal liver lesions: use of mangafodipir trisodium (MnDPDP)-enhanced MR images.
Karabacakoğlu A; Adigüzel Y; Karaköse S; Kayaçetin E; Haykir R
Turk J Gastroenterol; 2006 Sep; 17(3):164-71. PubMed ID: 16941248
[TBL] [Abstract][Full Text] [Related]
5. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
6. Mn-DPDP enhancement patterns of hepatocellular lesions on MR images.
Vogl TJ; Hamm B; Schnell B; McMahon C; Branding G; Lissner J; Wolf KJ
J Magn Reson Imaging; 1993; 3(1):51-8. PubMed ID: 8381314
[TBL] [Abstract][Full Text] [Related]
7. Focal liver lesions: MR imaging with Mn-DPDP--initial clinical results in 40 patients.
Hamm B; Vogl TJ; Branding G; Schnell B; Taupitz M; Wolf KJ; Lissner J
Radiology; 1992 Jan; 182(1):167-74. PubMed ID: 1309218
[TBL] [Abstract][Full Text] [Related]
8. Contrast-enhanced MRI of the liver with mangafodipir trisodium: imaging technique and results.
Sahani DV; O'Malley ME; Bhat S; Hahn PF; Saini S
J Comput Assist Tomogr; 2002; 26(2):216-22. PubMed ID: 11884777
[TBL] [Abstract][Full Text] [Related]
9. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents.
Youk JH; Lee JM; Kim CS
AJR Am J Roentgenol; 2004 Oct; 183(4):1049-54. PubMed ID: 15385303
[TBL] [Abstract][Full Text] [Related]
10. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Peterson MS; Oliver JH; Davis PL; Confer SR; Federle MP
Radiology; 1996 Jul; 200(1):69-77. PubMed ID: 8657947
[TBL] [Abstract][Full Text] [Related]
12. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
13. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA
AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
[TBL] [Abstract][Full Text] [Related]
14. Influence of the hepatobiliary contrast agent mangafodipir trisodium (MN-DPDP) on the imaging properties of abdominal organs.
Jung G; Heindel W; Krahe T; Kugel H; Walter C; Fischbach R; Klaus H; Lackner K
Magn Reson Imaging; 1998 Oct; 16(8):925-31. PubMed ID: 9814775
[TBL] [Abstract][Full Text] [Related]
15. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.
Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW
J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224
[TBL] [Abstract][Full Text] [Related]
16. MRI with mangafodipir trisodium in the detection of pancreatic tumours: comparison with helical CT.
Rieber A; Tomczak R; Nüssle K; Klaus H; Brambs HJ
Br J Radiol; 2000 Nov; 73(875):1165-9. PubMed ID: 11144793
[TBL] [Abstract][Full Text] [Related]
17. Defining intrahepatic biliary anatomy in living liver transplant donor candidates at mangafodipir trisodium-enhanced MR cholangiography versus conventional T2-weighted MR cholangiography.
Lee VS; Krinsky GA; Nazzaro CA; Chang JS; Babb JS; Lin JC; Morgan GR; Teperman LW
Radiology; 2004 Dec; 233(3):659-66. PubMed ID: 15516606
[TBL] [Abstract][Full Text] [Related]
18. Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Federle MP; Peterson MS; Oliver JH; Davis PL; Confer SR
Radiology; 1996 Feb; 198(2):567-72. PubMed ID: 8596867
[TBL] [Abstract][Full Text] [Related]
19. [The clinical value of Mn-DPDP: a new paramagnetic hepatobiliary contrast medium for magnetic resonance tomography of the liver].
Vogl TJ; Hamm B; Schnell B; Eibl-Eibesfeldt B; Steiner S; Lissner J
Rofo; 1991 Dec; 155(6):568-74. PubMed ID: 1764599
[TBL] [Abstract][Full Text] [Related]
20. Sequential use of gadolinium chelate and mangafodipir trisodium for the assessment of focal liver lesions: initial observations.
Martin DR; Semelka RC; Chung JJ; Balci NC; Wilber K
Magn Reson Imaging; 2000 Oct; 18(8):955-63. PubMed ID: 11121698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
